Le Wang1, Ju-Fang Shi2, Juan Zhu3, Hui-Yao Huang4, Ya-Na Bai5, Guo-Xiang Liu6, Xian-Zhen Liao7, A-Yan Mao8, Jian-Song Ren9, Xiao-Jie Sun10, Lan-Wei Guo11, Yi Fang12, Qi Zhou13, Heng-Min Ma14, Xiao-Jing Xing15, Lin Zhu16, Bing-Bing Song17, Ling-Bin Du18, Ling Mai19, Yu-Qin Liu20, Ying Ren21, Li Lan22, Jin-Yi Zhou23, Xiao Qi24, Xiao-Hua Sun25, Pei-An Lou26, Shou-Ling Wu27, Ni Li28, Kai Zhang29, Jie He30, Min Dai31. 1. Office of Cancer Screening, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. Electronic address: wangle021@hotmail.com. 2. Office of Cancer Screening, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. Electronic address: shijf@cicams.ac.cn. 3. Office of Cancer Screening, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. Electronic address: zhu_zhujuan@163.com. 4. Office of Cancer Screening, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. Electronic address: huanghy314@sina.cn. 5. Institute of Epidemiology and Health Statistics, Lanzhou University, Lanzhou, 730000, China. Electronic address: baiyana@lzu.edu.cn. 6. Department of Health Economics, School of Health Management, Harbin Medical University, Harbin, 150081, China. Electronic address: lgx6301@163.com. 7. Hunan Office for Cancer Control and Research, Hunan Cancer Hospital, Changsha, 410006, China. Electronic address: 125844068@qq.com. 8. Public Health Information Research Office, Institute of Medical Information, Chinese Academy of Medical Sciences, Beijing, 100020, China. Electronic address: myan77@126.com. 9. Office of Cancer Screening, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. Electronic address: renjiansong@sina.com. 10. Center for Health Management and Policy, Key Lab of Health Economics and Policy, Shandong University, Jinan, 250012, China. Electronic address: xiaojiesun@sdu.edu.cn. 11. Department of Institute of Tumor Research, Henan Cancer Hospital, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, 450008, China. Electronic address: guolanwei1019@126.com. 12. Department of Breast Surgical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. Electronic address: fangyi0501@163.net. 13. Chongqing Office for Cancer Control and Research, Chongqing Cancer Hospital, Chongqing, 400030, China. Electronic address: qizhou9128@163.com. 14. Science and Education Department of Public Health Division, Shandong Tumor Hospital, Jinan, 250117, China. Electronic address: sd_mahengmin@163.com. 15. Liaoning Office for Cancer Control and Research, Liaoning Cancer Hospital and Institute, Shenyang, 110042, China. Electronic address: 13940066477@163.com. 16. Teaching and Research Department, Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi, 830011, China. Electronic address: zhulintt2002@126.com. 17. Heilongjiang Office for Cancer Control and Research, Affiliated Cancer Hospital of Harbin Medical University, Harbin, 150081, China. Electronic address: bingbingsong2008@126.com. 18. Zhejiang Office for Cancer Control and Research, Zhejiang Cancer Hospital, Hangzhou, 310022, China. Electronic address: yjsdlb0407@126.com. 19. Department of Institute of Tumor Research, Henan Cancer Hospital, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, 450008, China. Electronic address: mailing65588018@163.com. 20. Cancer Epidemiology Research Center, Gansu Provincial Cancer Hospital, Lanzhou, 730050, China. Electronic address: liuyq970930@126.com. 21. Urban Office of Cancer Early Detection and Treatment, Tieling Central Hospital, Tieling, 112000, China. Electronic address: 595818013@qq.com. 22. Institute of Chronic Disease Prevention and Control, Harbin Center for Disease Control and Prevention, Harbin, 150056, China. Electronic address: llflx@sina.com. 23. Institute of Chronic Non-communicable Diseases Prevention and Control, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, 210009, China. Electronic address: zhoujinyi74@sina.com. 24. Department of Occupational Medicine, Tangshan People's Hospital, Tangshan, 063001, China. Electronic address: 13663350353@163.com. 25. Ningbo Clinical Cancer Prevention Guidance Center, Ningbo No. 2 Hospital, Ningbo, 315010, China. Electronic address: nbsunxh@126.com. 26. Department of Control and Prevention of Chronic Non-communicable Diseases, Xuzhou Center for Disease Control and Prevention, Xuzhou, 221006, China. Electronic address: lpa82835415@126.com. 27. Health Department of Kailuan Group, Kailuan General Hospital, Tangshan, 063000, China. Electronic address: drwusl@163.com. 28. Office of Cancer Screening, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. Electronic address: lini1240@hotmail.com. 29. Cancer Department of Physical Examination, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. Electronic address: kai87968@sina.com. 30. Department of Thoracic Surgery, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. Electronic address: prof.hejie@263.net. 31. Office of Cancer Screening, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. Electronic address: daimin2002@hotmail.com.
Abstract
BACKGROUND: Health-related quality of life and utility scores of patients with breast cancer and precancerous lesions are sparse in China. This study aimed to derive utility scores of patients with breast cancer and precancer in China. MATERIAL AND METHODS: An interviewer-administered cross-sectional survey was conducted in 12 provinces across China from 2013 to 2014. The three-level EuroQol-5-Dimension instrument was used to evaluate quality of life, and utility scores were generated using the Chinese value set. Univariate and multivariate analyses were performed to explore the determinants of utility scores. RESULTS: In total, 2626 breast cancer and 471 precancer patients were included. Mean age was 49.1 for breast cancer and 41.4 years for precancer (p < 0.001). Among the five dimensions, pain/discomfort was the most reported problem, 53.9% in breast cancer and 29.3% in precancer patients. Mean (95% CI) utility scores for breast cancer and precancer patients were estimated as 0.887 (0.875-0.899) and 0.781 (0.774-0.788), and the scores of breast cancer at stage-I, stage-II, stage-III and stage-IV were 0.789 (0.774-0.805), 0.793 (0.783-0.802), 0.774 (0.759-0.788) and 0.686 (0.654-0.717), respectively. Mean (95% CI) visual analogue scale scores for breast cancer and precancer were 75.6 (74.0-77.3) and 72.8 (72.3-73.3). Multiple regression showed advanced clinical stage, lower educational level, lower household income, surgery treatment, and undergoing treatment were independently associated with lower utility scores for breast cancer patients. CONCLUSION: The utility scores deteriorate with the severity of breast neoplasms. Detailed utility scores of breast cancer and precancer are fundamental for further cost-utility analysis in China.
BACKGROUND: Health-related quality of life and utility scores of patients with breast cancer and precancerous lesions are sparse in China. This study aimed to derive utility scores of patients with breast cancer and precancer in China. MATERIAL AND METHODS: An interviewer-administered cross-sectional survey was conducted in 12 provinces across China from 2013 to 2014. The three-level EuroQol-5-Dimension instrument was used to evaluate quality of life, and utility scores were generated using the Chinese value set. Univariate and multivariate analyses were performed to explore the determinants of utility scores. RESULTS: In total, 2626 breast cancer and 471 precancer patients were included. Mean age was 49.1 for breast cancer and 41.4 years for precancer (p < 0.001). Among the five dimensions, pain/discomfort was the most reported problem, 53.9% in breast cancer and 29.3% in precancer patients. Mean (95% CI) utility scores for breast cancer and precancer patients were estimated as 0.887 (0.875-0.899) and 0.781 (0.774-0.788), and the scores of breast cancer at stage-I, stage-II, stage-III and stage-IV were 0.789 (0.774-0.805), 0.793 (0.783-0.802), 0.774 (0.759-0.788) and 0.686 (0.654-0.717), respectively. Mean (95% CI) visual analogue scale scores for breast cancer and precancer were 75.6 (74.0-77.3) and 72.8 (72.3-73.3). Multiple regression showed advanced clinical stage, lower educational level, lower household income, surgery treatment, and undergoing treatment were independently associated with lower utility scores for breast cancerpatients. CONCLUSION: The utility scores deteriorate with the severity of breast neoplasms. Detailed utility scores of breast cancer and precancer are fundamental for further cost-utility analysis in China.
Authors: Juan Zhu; Xin-Xin Yan; Cheng-Cheng Liu; Hong Wang; Le Wang; Su-Mei Cao; Xian-Zhen Liao; Yun-Feng Xi; Yong Ji; Lin Lei; Hai-Fan Xiao; Hai-Jing Guan; Wen-Qiang Wei; Min Dai; Wanqing Chen; Ju-Fang Shi Journal: Qual Life Res Date: 2020-09-15 Impact factor: 4.147
Authors: Mingzhu Su; Xingxing Hua; Jialin Wang; Nengliang Yao; Deli Zhao; Weidong Liu; Yuewei Zou; Roger Anderson; Xiaojie Sun Journal: Qual Life Res Date: 2018-10-29 Impact factor: 4.147